Moveover, low expression of excision repair cross-complementation group 1 (ERCC1) was a significant independent favorable prognostic factor in patients with advanced GC who were receiving first-line chemotherapy regardless of the treatment regimen in JCOG9912 27. The gene discussed is ERCC1; the disease is gastric cancer.